Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Environmental groups urge Germany to cut oil and gas dependence - 2Humpback whale stranded on Germany's Baltic coast frees itself
- 3The most effective method to Pick the Ideal Lab Precious stone Wedding band
- 4Intriguing Strange Cruising Objections you Should Visit
- 5FDA proposes use of sunscreen ingredient popular in other countries
- Don't plan to cook on Thanksgiving? Here are the restaurants and fast food places that are scheduled to be open
- The most effective method to Comprehend the Variables Affecting Medical attendant Pay rates
- A definitive Manual for the Over-Ear Earphones
- Russia Creates New Military Branch Dedicated To Drone Warfare
- David Duchovny's new thriller has him stripping down at 65. But its chilling premise hits close to home.
- Taylor Frankie Paul's domestic violence case is fueling discussions about DARVO. Experts say terms like this shouldn't be used lightly.
- Vote In favor of Your Favored Language Learning Applications
- ‘Serving is not just a place’: Bayside Church Granite Bay reimagines annual mission amid conflict in Mexico
- EU Commission prepares €90bn Ukraine loan despite Hungary's veto
